A compounding effect from novel evidence of lactadherin as phospholipase inhibitor presents a likely explanation to the anti‐inflammatory and ameliorating effect of lactadherin in inflammatory bowels disease (Nyegaard, Novakovic, Rasmussen, & Gilbert, 2013). Here, MFGE8 is linked to inflammatory bowel disease.